Amyloid-β forms fibrils by nucleated conformational conversion of oligomers

被引:0
作者
Lee J. [1 ,2 ]
Culyba E.K. [1 ,2 ]
Powers E.T. [1 ]
Kelly J.W. [1 ,2 ]
机构
[1] Department of Chemistry, Scripps Research Institute, Skaggs Institute for Chemical Biology, San Diego, CA
[2] Department of Molecular and Experimental Medicine, Scripps Research Institute, San Diego, CA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nchembio.624
中图分类号
学科分类号
摘要
Amyloid-β amyloidogenesis is reported to occur via a nucleated polymerization mechanism. If this is true, the energetically unfavorable oligomeric nucleus should be very hard to detect. However, many laboratories have detected early nonfibrillar amyloid-β oligomers without observing amyloid fibrils, suggesting that a mechanistic revision may be needed. Here we introduce Cys-Cys-amyloid-β1-40, which cannot bind to the latent fluorophore FlAsH as a monomer, but can bind FlAsH as an nonfibrillar oligomer or as a fibril, rendering the conjugates fluorescent. Through FlAsH monitoring of Cys-Cys-amyloid-β1-40 aggregation, we found that amyloid-β1-40 rapidly and efficiently forms spherical oligomers in vitro (85% yield) that are kinetically competent to slowly convert to amyloid fibrils by a nucleated conformational conversion mechanism. This methodology was used to show that plasmalogen ethanolamine vesicles eliminate the proteotoxicity-associated oligomerization phase of amyloid-β amyloidogenesis while allowing fibril formation, rationalizing how low concentrations of plasmalogen ethanolamine in the brain are epidemiologically linked to Alzheimer's disease. © 2011 Nature America, Inc. All rights reserved.
引用
收藏
页码:602 / 609
页数:7
相关论文
共 51 条
[1]  
Selkoe D.J., Te molecular pathology of Alzheimer's disease, Neuron, 6, pp. 487-498, (1991)
[2]  
Hardy J., The Alzheimer family of diseases: Many etiologies, one pathogenesis?, Proceedings of the National Academy of Sciences of the United States of America, 94, 6, pp. 2095-2097, (1997)
[3]  
Holtzman D.M., Morris J.C., Goate A.M., Alzheimer's disease: The challenge of the second century, Sci. Transl. Med., 3, (2011)
[4]  
Klein W.L., Krafft G.A., Finch C.E., Targeting small A β oligomers: The solution to an Alzheimer's disease conundrum?, Trends in Neurosciences, 24, 4, pp. 219-224, (2001)
[5]  
Walsh D.M., Selkoe D.J., Aβ oligomers - A decade of discovery, J. Neurochem., 101, pp. 1172-1184, (2007)
[6]  
Shankar G.M., Et al., Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory, Nat. Med., 14, pp. 837-842, (2008)
[7]  
Shoji M., Et al., Production of the Alzheimer amyloid β protein by normal proteolytic processing, Science, 258, pp. 126-129, (1992)
[8]  
Garzon-Rodriguez W., Sepulveda-Becerra M., Milton S., Glabe C.G., Soluble amyloid Aβ-(1-40) exists as a stable dimer at low concentrations, Journal of Biological Chemistry, 272, 34, pp. 21037-21044, (1997)
[9]  
Ono K., Condron M.M., Teplow D.B., Structure-neurotoxicity relationships of amyloid β-protein oligomers, Proc. Natl. Acad. Sci. USA, 106, pp. 14745-14750, (2009)
[10]  
Bernstein S.L., Et al., Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease, Nat. Chem., 1, pp. 326-331, (2009)